Baxter International Inc $ 76.42 -0.73 (-0.95%)
Warning! GuruFocus has detected 6 Good signs with BAX. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for BAX (Baxter International Inc) from 1990 to Mar 04 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Baxter International stock (BAX) PE ratio as of Mar 04 2021 is 35.71. More Details
Baxter International PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Baxter International PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NYSE:RMD NAS:ISRG NYSE:BDX NYSE:TFX NYSE:WST NYSE:COO NAS:HOLX NYSE:STE NAS:MASI NYSE:VAR XPAR:EL OCSE:COLO B TSE:7741 XSWX:ALC TSE:4543 XPAR:DIM XTER:SRT TSE:7733 XSWX:SOON XSWX:STMN
Traded in other countries BAX.Austria B1AX34.Brazil BTL.Germany BAX.Mexico BAX.Switzerland 0QK8.UK BAX.USA
Address One Baxter Parkway, Deerfield, IL, USA, 60015
Baxter manufactures medical products across seven major reported business segments. The renal segment (32% of 2019 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while its acute therapies segment (5%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (25% of sales) sells IV pumps, administrative sets, and solutions while its nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segment (19% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (8% of sales) provides hemostastic products and biosurgical sealants. Contract manufacturing rounds out the remaining sales.